Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Monday.Shares of Intapp, Inc. (NASDAQ:INTA) fell sharply in today's pre-market trading after Opp
Express News | Myricx Bio Announces £90M ($114M) Series a Financing to Advance Its Novel Nmti-ADC Therapeutics Into Clinical Development
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Numerous ADC Therapeutics Insiders Sold Stock: Not A Positive Omen
ADC Therapeutics SA (NYSE:ADCT) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When analyzing insider transactions, it is usually more valuab
ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Trending Stocks Today: NANO Nuclear Energy Inches up 8.83% Post-Market
June 28th - US stocks trending post-market.Gainers: $NANO Nuclear Energy(NNE.US)$ climbs 8.83% to $25.51 with a turnover of $5.29 million. $Ginkgo Bioworks(DNA.US)$ up 3.2% to $0.35 with a turnover of
ADC Therapeutics Is Set To Join The Russell 2000 Index And The Broad-market Russell 3000 Index After The 2024 Russell Us Indexes Annual Reconstitution, Effective At The Open Of US Equity Markets On Monday, July 1, 2024
ADC Therapeutics Is Set To Join The Russell 2000 Index And The Broad-market Russell 3000 Index After The 2024 Russell Us Indexes Annual Reconstitution, Effective At The Open Of US Equity Markets On Mo
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company's common shares to three new employees on June 3, 2024 (each, a "Grant").
Express News | Cantor Fitzgerald Initiates Coverage On ADC Therapeutics With Overweight Rating
Why Investors Shouldn't Be Surprised By ADC Therapeutics SA's (NYSE:ADCT) 26% Share Price Plunge
ADC Therapeutics SA (NYSE:ADCT) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. Looking at the bigger picture, even afte
ADC Therapeutics Down 7% Following New Corporate Presentation
ADC Therapeutics Unveils Strategic Insights in New Presentation
Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 79.78% HC Wainwright & Co. $9 → $8 Maintains Buy 04/15/2024 102.25% HC Wainwright & Co. → $9 Re
Express News | ADC Therapeutics SA : H.c. Wainwright Cuts Target Price to $8 From $9
ADC Therapeutics Ltd's Business At Risk: The Perils of Limited Control in Clinical Trials
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q1 2024 Earnings Conference
The following is a summary of the ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript:Financial Performance:ADC Therapeutics SA reported Q1 2024 revenue of $17.8 million, a 7% sequential incre